New COVID Variant ‘Cicada’ Spreads in 31 States, Prompting Public Health Watch

As of early April 2026, the BA.3.2 COVID-19 variant, nicknamed “Cicada,” has been detected in at least 31 U.S. states, according to the Centers for Disease Control and Prevention (CDC). This heavily mutated strain, which emerged over a year ago, has begun to gain traction amid declining national infection rates, raising concerns among public health officials.

Understanding the Cicada Variant

The BA.3.2 variant, also known as “Cicada,” has a unique set of genetic mutations in its spike protein that may allow it to evade immunity from prior infections or vaccines, as noted in a recent study published in the CDC’s *Morbidity and Mortality Weekly Report*. These mutations have prompted the World Health Organization (WHO) to classify BA.3.2 as a “variant under monitoring” since December 2025.

“It has a lot of mutations that may cause it to look different to your immune system,” said Andrew Pekosz, Ph.D., a virologist at the Johns Hopkins Bloomberg School of Public Health. “These genetic changes have the potential to reduce protection from a previous infection or vaccination.”

The variant’s nickname, “Cicada,” was coined by T. Ryan Gregory, Ph.D., a professor of evolutionary biology at the University of Guelph. Like the insect, BA.3.2 “spent its first few years underground before re-emerging as a potential major variant,” Gregory explained.

MRNA Vaccines: Evolution and Efficacy

MRNA vaccines, first widely deployed during the COVID-19 pandemic, continue to evolve as researchers address emerging variants. While the current vaccines offer protection against severe disease, their effectiveness against newer strains like BA.3.2 is under active study. The CDC and other health agencies are closely monitoring real-world data to assess vaccine performance.

“mRNA vaccines are a preventive treatment that helps your body learn to fight diseases,” according to the Cleveland Clinic. “They’re currently only available for COVID-19, but the technology holds promise for future outbreaks.”

Experts emphasize that while mRNA vaccines have proven highly effective, their development requires continuous adaptation to combat viral mutations. The long-term success of this technology hinges on ongoing research and global collaboration.

Public Health Response and Next Steps

Public health officials are urging vaccination and booster uptake to mitigate the spread of BA.3.2. The CDC recommends that individuals stay informed about local infection rates and follow guidelines for masks and social distancing in high-risk settings.

“The most prevalent strains circulating in the U.S. right now are closely related, with slight genetic differences,” said Pekosz. “But BA.3.2 stands out due to its unique mutations, which we’re tracking closely.”

As the variant continues to spread, researchers are working to update vaccine formulations and develop new therapeutic strategies. The coming months will be critical in determining how effectively public health measures can curb its impact.

For the latest updates on the Cicada variant and vaccine developments, visit the CDC website or consult trusted health authorities.